BrainStorm Cell Therapeutics Reports Third Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 2c
November 15, 2016 9:19 AM ESTBrainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.09), $0.02 better than the analyst estimate of ($0.11).
As of September 30, 2016, the Company had cash, cash equivalents, and short-term deposits of approximately $11.2 million.
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
... More